The ESMO Breast Cancer 2024 programme is online!
Learning objectives
- To update your knowledge on the fast-developing field of breast cancer
- To understand recent developments in novel diagnostics, biomarkers and treatments in breast cancer
- To be updated on the rapid development of novel antibody drug conjugates for breast cancer
- To be informed on new strategies for Luminal, HER2 positive, HER2-low and triple negative breast cancer
- To understand special considerations for different subgroups of patients with breast cancer
Audience
The ESMO Breast Cancer is a congress designed for breast cancer researchers and clinicians who have a specific interest in innovation (including translational research, new agents, molecular and functional diagnostics, biomarkers and cutting-edge research applications in the clinical setting) and care. It will be a multidisciplinary meeting with a global scope, involving top scientists.
Accreditation
ESMO-MORA: The ESMO Breast Cancer 2024 programme has been accredited with 17 ESMO-MORA category 1 points. Recertification is necessary for medical oncologists to remain professionally certified by ESMO. It also guarantees that a certified medical oncologist has continued to update her/his knowledge and still possess the necessary skills and standards for the practice of medical oncology. See here for further details.
Disclaimer
All Speakers and Discussants are required to declare their interests, if any, and include a Declaration of Interest (DOI) slide at the start of their presentation(s).
The experts invited by ESMO as Discussants are selected on an individual basis to provide their own interpretation of the data and are not acting as ESMO spokespersons.
The ESMO recommendations on the clinical utility of new drugs are only presented in the ESMO Clinical Practice Guidelines and such recommendations represent the only official position of ESMO.